A vaccine against Campylobacter does not exist but represents a major unmet medical and industrial need. To date, the high variability of Campylobacter jejuni (main gastroenteritis causing member of the Campylobacter family) with more than 60 serotypes, prevents a universal vaccine generation against all species by conventional vaccine strategies.
Malcisbo’s glycoplatform technology offers the development of a broad-spectrum vaccine for broiler chicken covering all serotypes by reducing the contamination of chicken meat. It will be easy to apply and low in production costs.
We have designed a live, oral Campylobacter vaccine using a Salmonella based glycoconjugate for use in broiler chickens. By manipulation of the Salmonella vector bacterium the highly conserved protein bound N-glycan of Campylobacter jejuni and C. coli is expressed on the outer membrane of the bacterial surface.